Anika Therapeutics, Inc. (ANIK) has disclosed a new risk, in the Economy & Political Environment category.
Anika Therapeutics, Inc. may face significant challenges stemming from the geopolitical tensions in Ukraine and the Middle East, which could disrupt its business operations and supply chains. The unpredictable nature of these conflicts poses a risk of increased inflation, energy price hikes, and raw material shortages, potentially escalating operational costs. Furthermore, the company is at risk of indirect impacts such as cyber threats, adverse trade policies, and capital market volatility. These factors collectively threaten to amplify existing risks and adversely affect Anika’s financial stability and business continuity.
Overall, Wall Street has a Moderate Buy consensus rating on ANIK stock based on 2 Buys.
To learn more about Anika Therapeutics, Inc.’s risk factors, click here.